“…Early life choline supplementation in rats, either prenatally, neonatally, or post-weaning, exerts neuroprotection in a wide array of disease models, including epilepsy (Wong-Goodrich et al, 2008b; 2011), Down syndrome (Strupp et al, 2016), Rett syndrome (Nag and Berger-Sweeney et al, 2007; Nag et al, 2009), fetal alcohol syndrome (Thomas et al, 2003; 2007; Schneider and Thomas, 2016), depression (Glenn et al, 2012; McCall et al, 2015: Schulz et al, 2014), and schizophrenia (Corriveau and Glenn, 2012; Stevens et al, 2008; 2014). In addition to these disease models, early life choline supplementation also attenuates the effects of exposure to the neurotoxin, MK-801 (Guo-Ross et al, 2002; 2003). MK-801 is a noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist (Wong et al, 1986) that blocks the activity of the excitatory neurotransmitter, glutamate, preventing it from activating the NMDA receptor.…”